Oncologists discuss long-term ibrutinib use, cardiovascular risks with BTK inhibitors, and emerging fixed-duration acalabrutinib-venetoclax therapy in CLL.
News|Articles|April 1, 2026
7 Upcoming FDA Decisions in Q2 2026 to Watch
Author(s)Sabrina Serani
Fact checked by: Andrea Eleazar, MHS
Discover the critical Q2 2026 FDA decisions for Dato-DXd in TNBC and Orca-T in blood cancers, set to transform survival outcomes and precision oncology care.
Advertisement
Advertisement
The second quarter of 2026 stands as a pivotal window for the oncology and hematology sectors, with several high-stakes FDA decisions poised to reshape the treatment landscape for complex malignancies. From novel antibody-drug conjugates to cutting-edge allogeneic T-cell immunotherapies, the upcoming regulatory rulings reflect a continued push toward precision medicine and improved survival outcomes for patients with limited options.
Related to this article
The FDA has approved pimicotinib (Pimjetmi) at 50 mg once daily for adults with symptomatic tenosynovial giant cell tumor, based on the phase 3 MANEUVER study.
Updated phase 2 data showed a 60% ORR and 86% CNS ORR with frontline silevertinib in non-classical EGFR-mutant NSCLC; FDA discussion supported a phase 3 trial in 2027.
Patients with relapsed or refractory CTCL who responded to denileukin diftitox-cxdl experienced improvements in skin-related quality of life and overall well-being in Study 302.
Among patients surveyed, 92% preferred home-based treatment, while nationwide modeling projected substantial savings in oncology resources.
During a live event, Pedro Barata, MD, MSc, and participating oncologists discussed how efficacy, tolerability, and clinical evidence inform subsequent-line treatment selection for metastatic clear cell renal cell carcinoma.
Imneskibart showed promising outcomes and tolerability in patients who had previously received immune checkpoint inhibition for either melanoma or lung adenocarcinoma.
Renuka Iyer, MD, explains how NCCN is digitizing its guidelines with structured data to support AI tools, prior authorization, and point-of-care access.
Advertisement
Advertisement